immunotherapy

NovalGen to Begin World’s First Clinical Trial for a Self-Regulating Immunotherapy

LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The world’s first therapeutic drug to be equipped with NovalGen’s pioneering AutoRegulation (AR)…

4 months ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

NEEDHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical…

4 months ago

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational…

4 months ago

ALK and GenSci partner to expand the AIT market in China

Inside Information GenSci is granted exclusive rights to ALK’s house dust mite AIT products in China. ALK will be eligible…

4 months ago

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement…

4 months ago

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement…

4 months ago

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment…

4 months ago

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment…

4 months ago

Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate

SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) today announced…

4 months ago

Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results

 Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients   Six-month…

4 months ago